For decades, scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen. After years ...

Single-pill treatment proves as effective at suppressing virus as multi-pill therapy, while long-acting preventive injections ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...